Literature DB >> 26188171

Central acylated ghrelin improves memory function and hippocampal AMPK activation and partly reverses the impairment of energy and glucose metabolism in rats infused with β-amyloid.

Suna Kang1, Na Rang Moon1, Da Sol Kim1, Sung Hoon Kim2, Sunmin Park3.   

Abstract

Ghrelin is a gastric hormone released during the fasting state that targets the hypothalamus where it induces hunger; however, emerging evidence suggests it may also affect memory function. We examined the effect of central acylated-ghrelin and DES-acetylated ghrelin (native ghrelin) on memory function and glucose metabolism in an experimentally induced Alzheimer's disease (AD) rat model. AD rats were divided into 3 groups and Non-AD rats were used as a normal-control group. Each rat in the AD groups had intracerebroventricular (ICV) infusion of β-amyloid (25-35; 16.8nmol/day) into the lateral ventricle for 3 days, and then the pumps were changed to infuse either acylated-ghrelin (0.2nmol/h; AD-G), DES-acylated ghrelin (0.2nmol/h; AD-DES-G), or saline (control; AD-C) for 3 weeks. The Non-AD group had ICV infusion of β-amyloid (35-25) which does not deposit in the hippocampus. During the next 3 weeks memory function, food intake, body weight gain, body fat composition, and glucose metabolism were measured. AD-C exhibited greater β-amyloid deposition compared to Non-AD-C, and AD-G suppressed the increased β-amyloid deposition and potentiated the phosphorylation AMPK. In addition, AD-G increased the phosphorylation GSK and decreased the phosphorylation of Tau in comparison to AD-C and AD-DES-G. Cognitive function, measured by passive avoidance and water maze tests, was much lower in AD-C than Non-AD-C whereas AD-G but not AD-DES-G prevented the decrease (p<0.021). Body weight gain was lower in AD-C group than Non-AD-C group without changing epididymal fat mass. AD-G reversed the decrease in body weight which was due to increased energy intake and decreased energy expenditure. The AD-G group exhibited a decrease in the second part of serum glucose levels during an oral glucose tolerance test (OGTT) compared to the AD-C and AD-DES-G group (p<0.009). However, area under the curve of insulin during the first part of OGTT was higher in AD-DES-G than other groups, whereas during the second part it was suppressed in AD-G as much as Non-AD. In conclusion, central acylated ghrelin in rats prevented the deterioration of memory function, and energy and glucose metabolisms were partially improved, possibly due to less β-amyloid accumulation. This research suggests that interventions such as intermittent fasting to facilitate sustained elevations of acyl-ghrelin should be investigated for cognitive and metabolic benefits, especially in person with early symptoms of memory impairment.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cognitive function; Energy; Ghrelin; Glucose; Tau

Mesh:

Substances:

Year:  2015        PMID: 26188171     DOI: 10.1016/j.peptides.2015.07.005

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  10 in total

1.  Intermittent fasting protects against the deterioration of cognitive function, energy metabolism and dyslipidemia in Alzheimer's disease-induced estrogen deficient rats.

Authors:  Bae Kun Shin; Suna Kang; Da Sol Kim; Sunmin Park
Journal:  Exp Biol Med (Maywood)       Date:  2018-01-07

Review 2.  Ghrelin and Neurodegenerative Disorders-a Review.

Authors:  Limin Shi; Xixun Du; Hong Jiang; Junxia Xie
Journal:  Mol Neurobiol       Date:  2016-01-26       Impact factor: 5.590

3.  Nacre extract from pearl oyster attenuates amyloid beta-induced memory impairment.

Authors:  Yamato Yotsuya; Yasushi Hasegawa
Journal:  J Nat Med       Date:  2022-01-19       Impact factor: 2.343

4.  Subtle Alterations in Spatial Memory Induced by Amyloid Peptides Infusion in Rats.

Authors:  Priscila Tavares Macêdo; Antônio C Q Aquino; Ywlliane S R Meurer; Luiz E M Brandão; Clarissa L C Campêlo; Ramon H Lima; Marcos R Costa; Alessandra M Ribeiro; Regina H Silva
Journal:  Front Aging Neurosci       Date:  2018-01-30       Impact factor: 5.750

Review 5.  Therapeutic Potential of Targeting the Ghrelin Pathway.

Authors:  Gustav Colldén; Matthias H Tschöp; Timo D Müller
Journal:  Int J Mol Sci       Date:  2017-04-11       Impact factor: 5.923

6.  Ghrelin reduces cerebral ischemic injury in rats by reducing M1 microglia/macrophages.

Authors:  Rong Tian; Gengsheng Mao
Journal:  Eur J Histochem       Date:  2022-01-12       Impact factor: 3.188

7.  Design and Experimental Evaluation of a Peptide Antagonist against Amyloid β(1-42) Interactions with Calmodulin and Calbindin-D28k.

Authors:  Jairo Salazar; Joana Poejo; Ana M Mata; Alejandro K Samhan-Arias; Carlos Gutierrez-Merino
Journal:  Int J Mol Sci       Date:  2022-02-18       Impact factor: 5.923

8.  Acyl Ghrelin Improves Synapse Recovery in an In Vitro Model of Postanoxic Encephalopathy.

Authors:  Irina I Stoyanova; Jeannette Hofmeijer; Michel J A M van Putten; Joost le Feber
Journal:  Mol Neurobiol       Date:  2015-11-06       Impact factor: 5.590

Review 9.  The Neurocognitive Effects of Ghrelin-induced Signaling on the Hippocampus: A Promising Approach to Alzheimer's Disease.

Authors:  Robert S Seminara; Charan Jeet; Sharmi Biswas; Bushra Kanwal; Waleed Iftikhar; Md Sakibuzzaman; Ian H Rutkofsky
Journal:  Cureus       Date:  2018-09-11

Review 10.  Neuropeptides Exert Neuroprotective Effects in Alzheimer's Disease.

Authors:  Xin-Yi Chen; Yi-Feng Du; Lei Chen
Journal:  Front Mol Neurosci       Date:  2019-01-11       Impact factor: 5.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.